697762-66-6

Basic information

• Product Name: 1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester
• Synonyms: 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[1-(S)-tert-butyldimethylsilyloxymethyl-2-methylprop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester;(S)-ethyl 1-(1-(tert-butyldimethylsilyloxy)-3-methylbutan-2-yl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate;1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester
• CAS NO: 697762-66-6
• Molecular Formula: C₃₀H₃₈ClF₂NO₄Si
• Molecular Weight: 578.1623264
• Mol File: 697762-66-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester(697762-66-6)
• EPA Substance Registry System: 1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester(697762-66-6)

Safety Data

• Hazardous Substances Data: 697762-66-6(Hazardous Substances Data)

Usage

General Description

The chemical "1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester" is a complex compound with a long and specific name. It is an ethyl ester derivative of a quinolone antibiotic, with a molecular structure that includes a fluoroquinolone core, a tert-butyldimethylsilyloxy group, and a chlorofluorobenzyl group. It is likely to have antibacterial properties due to its similarity to other quinolone antibiotics, and the specific chemical modifications may affect its pharmacokinetics and potency. 1-((S)-1-tert-butyldiMethylsilyloxyMethyl-2-Methylpropyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester has the potential to be important for pharmaceutical research and the development of new antibiotics.

Upstream product

• 85070-47-9 1-(bromomethyl)-3-chloro-2-fluorobenzene 
• 697762-59-7 C₁₇H₂₀F₂INO₄ 
• 72-18-4 L-valine 
• 161531-51-7 2,4-difluoro-5-iodobenzoic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 2026-48-4 (S)-valinol 
• 697762-60-0 7-fluoro-1-(1(S)-hydroxymethyl-2-methylprop-1-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 697762-39-3 ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(dimethylamino)acrylate 
• 869893-91-4 3-chloro-2-fluorobenzyl zinc bromide 
• 870294-02-3 1-((2S)-1-tert-butyldimethylsilyloxy-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 

Downstream Products

• 1261283-95-7 1(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-97-9 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-99-1 1-(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261284-01-8 6-(3-chloro-2-fluorobenzyl)-7-methoxy-1-[1-(S)-2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-94-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid dicyclohexylamine salt 
• 697761-98-1 elvitegravir 
• 869893-92-5 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF ELVITEGRAVIR

The present invention relates to improved process for the preparation of elvitegravir (12), wherein the compound of formula (6) is protected with suitable protecting agents and further reacted with formula (9) in the presence of tetrakis(triphenylphosphin

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

The viral enzyme integrase is essential for the replication of human immunodeficiency virus type 1 (HIV-1) and represents a remaining target for antiretroviral drugs. Here, we describe the modification of a quinolone antibiotic to produce the novel integr